Press Release
Feb 15, 2024
Investing in the Next Frontier of Healthcare: Navigating Opportunities in In Vivo Gene Editing Technologies
YolTech Therapeutics operates as a gene editing company at the forefront of medical innovation
Share
LATESTNEWS
-
YolTech Announces Interim Clinical Data from Investigator-Initiated Trials of YOLT-203 in Primary Hyperoxaluria Type 1 to be Presented at the American Society of Nephrology (ASN) Kidney Week 2026
Oct 23, 2026
-
YolTech Appoints Nitin Patel, BM BCh, as U.S. Chief Medical Officer
Oct 14, 2026
-
YolTech Presented Proof-of-Concept Data from Clinical Trial of YOLT-202 in PiZZ Alpha-1 Antitrypsin Deficiency (AATD) Patients at European Respiratory Society Congress 2026
Sep 07, 2026
